EA201791745A1 - Производные тетрагидропиранилбензамида - Google Patents

Производные тетрагидропиранилбензамида

Info

Publication number
EA201791745A1
EA201791745A1 EA201791745A EA201791745A EA201791745A1 EA 201791745 A1 EA201791745 A1 EA 201791745A1 EA 201791745 A EA201791745 A EA 201791745A EA 201791745 A EA201791745 A EA 201791745A EA 201791745 A1 EA201791745 A1 EA 201791745A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tetrahydropyranilbenzamide
derivatives
compounds
methods
diabetes
Prior art date
Application number
EA201791745A
Other languages
English (en)
Inventor
Чжи Лун Ху
Лянь Чжу Лю
Тяньвэй Ма
Хайчжэнь Чжан
Цзинье Чжоу
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201791745A1 publication Critical patent/EA201791745A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В настоящем изобретении предложены соединения формулыгде R, R1-R3 описаны в настоящем документе; способы лечения пациентов, страдающих диабетом, с применением указанных соединений, и способы получения указанных соединений.
EA201791745A 2015-03-03 2016-02-19 Производные тетрагидропиранилбензамида EA201791745A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/073563 WO2016138631A1 (en) 2015-03-03 2015-03-03 Imidazo benzamide compounds
PCT/CN2016/074083 WO2016138821A1 (en) 2015-03-03 2016-02-19 Tetrahydropyranyl benzamide derivatives

Publications (1)

Publication Number Publication Date
EA201791745A1 true EA201791745A1 (ru) 2018-01-31

Family

ID=56849060

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791745A EA201791745A1 (ru) 2015-03-03 2016-02-19 Производные тетрагидропиранилбензамида

Country Status (24)

Country Link
US (1) US10196385B2 (ru)
EP (1) EP3265460A4 (ru)
JP (1) JP2018507232A (ru)
KR (1) KR20170106483A (ru)
CN (1) CN107406436B (ru)
AU (1) AU2016228055B2 (ru)
BR (1) BR112017015448A2 (ru)
CA (1) CA2975413A1 (ru)
CL (1) CL2017002148A1 (ru)
CO (1) CO2017008721A2 (ru)
CR (1) CR20170354A (ru)
DO (1) DOP2017000196A (ru)
EA (1) EA201791745A1 (ru)
EC (1) ECSP17058071A (ru)
IL (1) IL253405A0 (ru)
MA (1) MA41641A (ru)
MX (1) MX2017011087A (ru)
PE (1) PE20171650A1 (ru)
PH (1) PH12017501560A1 (ru)
SG (1) SG11201706718RA (ru)
SV (1) SV2017005520A (ru)
TN (1) TN2017000372A1 (ru)
WO (2) WO2016138631A1 (ru)
ZA (1) ZA201704948B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014337A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2010101247A1 (ja) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するシクロヘキサン誘導体
CN102695414A (zh) * 2010-01-15 2012-09-26 默沙东公司 作为抗糖尿病化合物的噁二唑β-咔啉衍生物
JP5935154B2 (ja) * 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
WO2015120610A1 (en) 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound

Also Published As

Publication number Publication date
EP3265460A1 (en) 2018-01-10
WO2016138821A1 (en) 2016-09-09
CO2017008721A2 (es) 2018-01-05
US10196385B2 (en) 2019-02-05
PH12017501560A1 (en) 2018-02-05
BR112017015448A2 (pt) 2018-01-30
SV2017005520A (es) 2018-08-27
SG11201706718RA (en) 2017-09-28
CR20170354A (es) 2017-09-05
EP3265460A4 (en) 2018-08-08
TN2017000372A1 (en) 2019-01-16
PE20171650A1 (es) 2017-11-13
MA41641A (fr) 2018-01-09
CN107406436A (zh) 2017-11-28
CN107406436B (zh) 2021-02-26
CL2017002148A1 (es) 2018-04-13
CA2975413A1 (en) 2016-09-09
DOP2017000196A (es) 2017-09-15
ZA201704948B (en) 2019-02-27
WO2016138631A1 (en) 2016-09-09
AU2016228055B2 (en) 2018-06-07
ECSP17058071A (es) 2017-10-31
KR20170106483A (ko) 2017-09-20
IL253405A0 (en) 2017-09-28
MX2017011087A (es) 2017-11-10
AU2016228055A1 (en) 2017-08-17
JP2018507232A (ja) 2018-03-15
US20180194755A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201792471A1 (ru) Бигетероарильные соединения и их применения
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
EA201691541A1 (ru) Новые анти-baff антитела
EA201792287A1 (ru) Способы лечения рака
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
EA201790327A1 (ru) Соединения замещенного пиперидина
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1